Summit Therapeutics, Inc., shared on LinkedIn:
“Ivonescimab Monotherapy Demonstrates a Statistically Significant and Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China.
- Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab
- HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months
- PD-L1 High Expression Subgroup: Hazard Ratio = 0.58
- Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”
You can also read: Yüksel Ürün: Ivonescimab Delivers Significant Overall Survival Benefit in NSCLC
